Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS2 | P35228 | 2/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13027392 | 0.96 | KMT2A (0.34) | ACHETNKS2HTR2AHTR2CHTR2B | |
| SCHEMBL13027400 | 0.88 | CYP19A1 (0.41) | ACHELMNAMAPTALOX12NOS2 | |
| SCHEMBL13027629 | 0.85 | ACHE (0.31) | ACHEHTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL13027389 | 0.81 | TUBB1 (0.32) | TNKS2HTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL13027379 | 0.81 | HRH3 (0.40) | ACHEKMT2ALMNAMAPTMEN1 | |
| SCHEMBL13027403 | 0.80 | TAAR1 (0.53) | ACHEKMT2ALMNAMAPTALOX12 | |
| SCHEMBL30738465 | 0.80 | PTGS2 (0.34) | TNKS2KMT2ALMNAMAPTALOX12 | |
| SCHEMBL13027468 | 0.79 | HTR2A (0.41) | TNKS2HTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL15672349 | 0.79 | DHFR (0.41) | ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL574710 | 0.78 | TAAR1 (0.46) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873415-B2 | Substrate with water repellent oil repellent layer, vapor deposition material, and method for producing substrate with water repellent oil repellent layer | AGC Inc. (JP) | 2024-01-16 | — | — | US | disclosed |
| US-20230220236-A1 | COMPOSITION, SUBSTRATE WITH SURFACE LAYER, METHOD FOR PRODUCING SUBSTRATE WITH SURFACE LAYER, COMPOUNDS, AND METHODS FOR PRODUCING COMPOUNDS | AGC Inc. (JP) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220236-A1 | COMPOSITION, SUBSTRATE WITH SURFACE LAYER, METHOD FOR PRODUCING SUBSTRATE WITH SURFACE LAYER, COMPOUNDS, AND METHODS FOR PRODUCING COMPOUNDS | ZRANB2, ITGB1, ITGB2 | PGK1 3308/4885PGK2 3472/4885ACHE 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.